盐酸伊立替康致迟发性腹泻作用机制及防治的研究进展

中国药物警戒 ›› 2012, Vol. 9 ›› Issue (9): 535-538.

盐酸伊立替康致迟发性腹泻作用机制及防治的研究进展

张晓光, 张侠

北京军区总医院肿瘤科,北京 100700

收稿日期:2012-02-08 出版日期:2012-09-10 发布日期:2015-08-07
作者简介:张晓光,女,硕士在读,恶性肿瘤防治。

Study on the Development of the Mechanism of Action, Prevention and Treatment for Irinotecan-induced Diarrhea

ZHANG Xiao-guang, ZHANG Xia

Department of Oncology, the Military General Hospital of Beijing PLA, Beijing 100700, China

Received:2012-02-08 Online:2012-09-10 Published:2015-08-07

摘要/Abstract

摘要： 目的综述伊立替康致迟发性腹泻发生机制以及预防和治疗药物的研究进展。方法检索PUBMED和中国知网2001-2011年国内外相关文献,对伊立替康致迟发性腹泻进行分析。结果伊立替康体内代谢过程受多种代谢酶、基因、蛋白的影响,多种药物对迟发性腹泻有不用程度的治疗作用。结论了解伊立替康致迟发性腹泻的机制,可进一步提高该药的临床有效性和安全性。

关键词: 伊立替康, 腹泻, 尿苷二磷酸葡萄糖醛酸转移酶（UGT1A1）, 防治

Abstract: ObjectiveTo review the mechanism of irinotecan-induced type diarrhea and the prevention and therapy for it. MethodsAnalyze the irinotecan-induced diarrhea based on the relevance literature searched on the PUBMED and CNKI from 2001 to 2011. ResultsMetabolic processes of irinotecan is affected by a variety of metabolic enzymes, genes and proteins. Many drugs have different therapeutic effects for the delayed diarrhea. Conlusion Make an in-depth understanding of the mechanism of irinotecan-induced delayed diarrhea, which can further improve its safety and efficacy.

Key words: irinotecan, diarrhea, UGT1A1, prevention and treatment

张晓光, 张侠. 盐酸伊立替康致迟发性腹泻作用机制及防治的研究进展[J]. 中国药物警戒, 2012, 9(9): 535-538.

ZHANG Xiao-guang, ZHANG Xia. Study on the Development of the Mechanism of Action, Prevention and Treatment for Irinotecan-induced Diarrhea[J]. Chinese Journal of Pharmacovigilance, 2012, 9(9): 535-538.

参考文献

[1] Zhou Y,Gwadry F G,Reinhold W C,et al.Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage:microarray analysis of dose and time-dependent effects[J].Cancer Res,2002,62(6):1688-95.
[2] 孙华君,王翠松.伊立替康肠毒性预防研究进展[J].世界临床药物,2005,26(5):286-291.
[3] Stein A,Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management[J]. Ther Adv Med Oncol. 2010,2(1):51-63.
[4] Hicks LD,Hyatt J L,Stoddard S,et al.Improved,se-lective,human intestinal carboxylesterase inhibitors designed to nodulate 7-ethyl-
10-[4-(1-p iperidino)-1-piperidino] carbonyloxy-camp tothecin
5 (irinotecan; CPT-11) toxicity[J]. M ed Chem, 2009, 52(12): 3742-
6 3752.
[5] Jessica M. van der Bol, Ron H.J Mathijssen, Geert-Jan M. Creemers,et al.A CYP3A4 Phenotype-Based Dosing Algorithm for Individ-
ualized Treatment of Irinotecan [J]. Clin Cancer Res,2010,2(16)：736.
[6] Andrea M. Stringer ,Rachel J. Gibson ,Richard M,et al.Irinotecan-induced mucositis is associated with changes in intestinal mucins[J] .Cancer Chemother Pharmacol ,2009,64:123-132.
[7] Stringer A M,Gibson R J,Logann R M,et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat[J].Exp Biol MedJanuary ,2007,;232(1):96-106.
[8] Antonello Di Paolo,Guido Bocci,Marialuisa Polillo,et al. Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity[J]. Current Drug Metabolism, 2011, 12: 932-943.
[9] Cecchin E,Innocenti F,D'Andrea M,et al.Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan[J].Clin. Oncol,2009, 27(15):2457-2465.
[10] Ando, Y, Saka, H, Asai, G, et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan[J].Ann. Oncol., 1998, 9(8):845-847.